Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Bioavailability of BI 1815368 in Healthy Males
NCT05337592Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1815368 in diabetic macular edema (DME) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of any treatment-emergent adverse event, Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 to the last quantifiable data point and 1 more. Started Jun 2022; status: completed.
02
Drugs
BI 1815368
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05337592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337592.